4th Treg Directed Therapies Summit 2022

As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies. Promising proof-of-concept data and early clinical read outs have fueled further hype, and the industry now looks to demonstrate efficacy.

The 4^th Treg Directed Therapies Summit returns to Boston this May, bigger and better than ever before, boasting 2 tracks of unparalleled content to cater to cell-based, and non-cell-based experts alike. This is the only industry-focused meeting designed to bridge the gap between early discovery through clinical development of cell-based and non-cell-based Treg directed therapies to provide efficacious treatments for patients globally.

With 3 days of unrivalled content spanning the fundamental biology of Tregs, optimising early drug development, and streamlining clinical development, join with your team to:

• Optimise stable expansion of Tregs to maintain function to elicit durable responses
• Decode Treg interactions to optimise the mechanism of actions and inform biomarker development
• Rationalize activation, formulation & delivery strategy to induce antigen-specific tolerance  
• Supercharge CMC strategy to drive the modulation of antigen-specific responses to yield maximum clinical efficacy

200+ senior-level drug developers will be uniting in May to chase the holy grail of Treg-directed therapies. Don’t miss your chance to network with the avant-garde to inform your Treg pipeline and capitalise on the shared knowledge of this collaborative community.

Download the full event guide for the speaker faculty and session details.

Early Bird & Team Discounts available – Secure your place today